Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HR negative
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2099
;
5241
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
trastuzumab + pertuzumab
Sensitive
:
A2
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
trastuzumab + pertuzumab
Sensitive
:
A2
HR negative
HER2 Negative Breast Cancer
HR negative
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: B - Late Trials
trastuzumab + lapatinib
Sensitive
:
B
trastuzumab + lapatinib
Sensitive: B - Late Trials
trastuzumab + lapatinib
Sensitive
:
B
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
QL1209 (pertuzumab biosimilar)
Sensitive: B - Late Trials
QL1209 (pertuzumab biosimilar)
Sensitive
:
B
QL1209 (pertuzumab biosimilar)
Sensitive: B - Late Trials
QL1209 (pertuzumab biosimilar)
Sensitive
:
B
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
HR negative
HER2 Negative Breast Cancer
HR negative
HER2 Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: C2 – Inclusion Criteria
carboplatin + paclitaxel
Sensitive
:
C2
carboplatin + paclitaxel
Sensitive: C2 – Inclusion Criteria
carboplatin + paclitaxel
Sensitive
:
C2
HR negative
HER2 Negative Breast Cancer
HR negative
HER2 Negative Breast Cancer
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
tegafur/uracil
Sensitive: C3 – Early Trials
tegafur / uracil
Sensitive
:
C3
tegafur/uracil
Sensitive: C3 – Early Trials
tegafur / uracil
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
pertuzumab
Sensitive: C3 – Early Trials
pertuzumab
Sensitive
:
C3
pertuzumab
Sensitive: C3 – Early Trials
pertuzumab
Sensitive
:
C3
HR negative
HER2 Negative Breast Cancer
HR negative
HER2 Negative Breast Cancer
AMG 479
Sensitive: C3 – Early Trials
AMG 479
Sensitive
:
C3
AMG 479
Sensitive: C3 – Early Trials
AMG 479
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
pertuzumab + ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
pertuzumab + ado-trastuzumab emtansine
Sensitive
:
C3
pertuzumab + ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
pertuzumab + ado-trastuzumab emtansine
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
lapatinib
Sensitive: C3 – Early Trials
lapatinib
Sensitive
:
C3
lapatinib
Sensitive: C3 – Early Trials
lapatinib
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
pembrolizumab + pertuzumab + trastuzumab-qyyp
Sensitive: C3 – Early Trials
pembrolizumab + pertuzumab + trastuzumab-qyyp
Sensitive
:
C3
pembrolizumab + pertuzumab + trastuzumab-qyyp
Sensitive: C3 – Early Trials
pembrolizumab + pertuzumab + trastuzumab-qyyp
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive: C3 – Early Trials
trastuzumab + pyrotinib
Sensitive
:
C3
trastuzumab + pyrotinib
Sensitive: C3 – Early Trials
trastuzumab + pyrotinib
Sensitive
:
C3
HR negative
HER2 Negative Breast Cancer
HR negative
HER2 Negative Breast Cancer
durvalumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
durvalumab + fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
durvalumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
durvalumab + fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
HR negative
HER2 Negative Breast Cancer
HR negative
HER2 Negative Breast Cancer
cemiplimab-rwlc
Sensitive: C3 – Early Trials
cemiplimab-rwlc
Sensitive
:
C3
cemiplimab-rwlc
Sensitive: C3 – Early Trials
cemiplimab-rwlc
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive: C3 – Early Trials
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive
:
C3
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive: C3 – Early Trials
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
paclitaxel + doxorubicin hydrochloride
Sensitive: C3 – Early Trials
paclitaxel + doxorubicin hydrochloride
Sensitive
:
C3
paclitaxel + doxorubicin hydrochloride
Sensitive: C3 – Early Trials
paclitaxel + doxorubicin hydrochloride
Sensitive
:
C3
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C4 – Case Studies
ado-trastuzumab emtansine
Sensitive
:
C4
ado-trastuzumab emtansine
Sensitive: C4 – Case Studies
ado-trastuzumab emtansine
Sensitive
:
C4
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
margetuximab-cmkb
Sensitive: C4 – Case Studies
margetuximab-cmkb
Sensitive
:
C4
margetuximab-cmkb
Sensitive: C4 – Case Studies
margetuximab-cmkb
Sensitive
:
C4
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
bevacizumab + disitamab vedotin
Sensitive: C4 – Case Studies
bevacizumab + disitamab vedotin
Sensitive
:
C4
bevacizumab + disitamab vedotin
Sensitive: C4 – Case Studies
bevacizumab + disitamab vedotin
Sensitive
:
C4
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
CDK19 inhibitor
Sensitive: D – Preclinical
CDK19 inhibitor
Sensitive
:
D
CDK19 inhibitor
Sensitive: D – Preclinical
CDK19 inhibitor
Sensitive
:
D
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
CDK8 inhibitor
Sensitive: D – Preclinical
CDK8 inhibitor
Sensitive
:
D
CDK8 inhibitor
Sensitive: D – Preclinical
CDK8 inhibitor
Sensitive
:
D
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
RVU120
Sensitive: D – Preclinical
RVU120
Sensitive
:
D
RVU120
Sensitive: D – Preclinical
RVU120
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login